An international team of scientists is preparing to launch multinational clinical trials after a new study published in Cancer Discovery on October 16, 2026, revealed that an existing lactation medication is associated with a significantly lower risk of postpartum breast cancer. Led in part by researchers at the University of British Columbia (UBC) in Vancouver and the Cancer Research Center of Salamanca in Spain, the research focuses on cabergoline, a prescription drug traditionally used to stop milk production after pregnancy loss or when nursing is not medically possible. By examining whether a post-weaning dose can safely help breast tissue reset after lactation, investigators hope to eventually offer high-risk women a less invasive preventive option than prophylactic surgery or long-term hormone therapy.

According to ecancer, the observational portion of the study found that women who took cabergoline to suppress milk production had an approximately 70 percent lower likelihood of developing breast cancer in subsequent years compared to those who did not receive the drug. Because historical health records can only demonstrate a statistical correlation rather than direct cause and effect, the research team is now moving forward with human clinical trials to test the medication's biological impact directly.

How Postpartum Breast Involution Works

To understand why a lactation medication might influence cancer risk, researchers examined the intense physical reorganization the mammary gland undergoes during and after pregnancy. During gestation, rising hormone levels cause milk-producing structures within the breast to branch out extensively. Once nursing concludes, those specialized cells are no longer needed, triggering a natural biological clean-up process known as involution.

Dr. Christopher Maxwell, a professor in UBC's faculty of medicine, investigator at the BC Children's Hospital Research Institute, and co-lead of the study, compared this cellular transition to a seasonal fruit tree. In the spring and summer, a tree grows branches, blossoms, and produces fruit before shedding what it no longer needs to prepare for winter.

"We think of involution as the breast's version of winter," Maxwell explained in a statement reported by ecancer. "It's a period when structures that were needed for pregnancy and breastfeeding reset for the future."

Breast cancer is the leading cause of cancer-related death among younger women, with the majority of these diagnoses occurring in the years following pregnancy. For women carrying inherited genetic mutations, such as alterations in the BRCA1 and TP53 genes responsible for repairing DNA and clearing damaged cells, this post-weaning clean-up process can be incomplete. According to Agencia SINC, an incomplete transition can leave behind damaged cells that may eventually become malignant.

Preclinical Findings and Observational Data

To test whether medication could assist this natural cellular clearance, scientists administered a single dose of cabergoline upon weaning to experimental mice carrying BRCA1 and TP53 mutations. In those laboratory models, the drug accelerated the post-weaning involution process, shrank the ductal area, reduced cell growth, decreased potentially precancerous tissue, and boosted the presence of immune cells responsible for clearing out damaged tissue. As a result, tumor incidence rates in the treated mice fell by about half.

The researchers then looked for similar patterns in human populations by analyzing retrospective medical records from Spain and Norway. While reports from ecancer and Redacción Médica indicate the analytic dataset included health records from more than 150,000 women in Catalonia and Norway, a separate report by Infobae describes a broader underlying population of more than 700,000 women across the two countries. Across the analyzed records, postpartum cabergoline use was linked to an estimated 69 to 70 percent lower relative risk of developing breast cancer during the follow-up period.

Scientists emphasize that these figures must be interpreted with caution. Jesús Pérez Losada, an investigator with the Spanish National Research Council (CSIC), noted in Redacción Médica that the statistic represents a relative difference between groups rather than a 70 percentage-point drop in an individual's personal probability of developing the disease, or a guarantee of protection. Furthermore, because the human data is retrospective and included a relatively small number of total cancer cases among women exposed to the drug, researchers cannot yet confirm that cabergoline directly caused the lower cancer rates.

Inside the Planned Multinational Clinical Trial

To move beyond observational correlations, the international team is organizing a controlled clinical study funded by the Gray Foundation. While some initial coverage referred broadly to upcoming clinical trials, specialist reporting from Redacción Médica specifies that the researchers are preparing a Phase II, randomized, double-blind, placebo-controlled trial slated to begin in 2027.

The trial aims to enroll 55 participants across sites in Canada, the United Kingdom, and Spain who carry a pathogenic BRCA1 variant. Under the study protocol, participating mothers will decide for themselves how long they wish to breastfeed their infants. Only after they have completely finished nursing and weaned their babies will they be given either cabergoline or a placebo.

Rather than tracking long-term cancer diagnoses or survival rates—which would require larger populations and decades of follow-up—this initial trial will evaluate intermediate biological markers in breast tissue linked to future cancer risk.

What This Means for Patients Today

With approximately one in eight women developing breast cancer during their lifetime, medical researchers are eager to find tolerable, short-term interventions that can intercept the disease before it starts. Because cabergoline is already an established, well-tolerated medication with few side effects when used for its approved postpartum indications, repurposing it as a brief post-weaning treatment is an attractive scientific hypothesis.

However, public health guidance and clinical standards remain unchanged. According to Medical Daily and Earth.com, cabergoline is neither approved nor proven to prevent breast cancer, and the current study does not justify taking the medication outside of its established medical indications. Patients at elevated genetic risk for breast cancer should continue consulting their oncologists and genetic counselors regarding proven risk-management strategies, such as enhanced imaging surveillance, approved risk-reducing medications, or preventive surgery.